Treatment-independent miRNA signature in blood of wilms tumor patients

BMC Genomics

Volumn 13, Issue 1, 2012, Pages

  Schmitt, Jana ^a   Backes, Christina ^a   Nourkami Tutdibi, Nasenien ^a   Leidinger, Petra ^a   Deutscher, Stephanie ^a   Beier, Markus ^b   Gessler, Manfred ^c   Graf, Norbert ^a   Lenhof, Hans Peter ^d   Keller, Andreas ^a   Meese, Eckart ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Febit Group   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 106A; MICRORNA 106B; MICRORNA 1204; MICRORNA 1246; MICRORNA 126; MICRORNA 1305; MICRORNA 144; MICRORNA 17; MICRORNA 18A; MICRORNA 18B; MICRORNA 197; MICRORNA 20A; MICRORNA 20B; MICRORNA 224; MICRORNA 373; MICRORNA 374A; MICRORNA 520; MICRORNA 766; MICRORNA 93; UNCLASSIFIED DRUG;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHILD; CLINICAL PROTOCOL; COMPUTER PROGRAM; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; PREOPERATIVE EVALUATION; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; SUPPORT VECTOR MACHINE;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; CLUSTER ANALYSIS; HUMANS; MICRORNAS; TRANSCRIPTOME; WILMS TUMOR;

EID: 84864763720     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-13-379     Document Type: Article

References (37)

1. Davidoff AM. Wilms' tumor. Curr Opin Pediatrics 2009, 21(3):357-364.
2. Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms' tumor. The SIOP studies. International Society of Pediatric Oncology. The Urologic Clinics of North Am 2000, 27(3):443-454. [http://www.ncbi.nlm.nih.gov/pubmed/10985144. [PMID: 10985144]].
3. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Müller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V, Staehler C, Beier M, Scheffler M, Büchler MW, Wischhusen J, Haeusler SFM, Dietl J, Hofmann S, Lenhof H, Schreiber S, Katus HA, Rottbauer W, Meder B, Hoheisel JD, Franke A, Meese E. Toward the blood-borne miRNome of human diseases. Nat Methods 2011,
4. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Archiv: An Int J Pathol 2008, 452:1-10.
5. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269.
6. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, Junker K. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J of Urology 2011, 29(3):367-373.
7. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009, 35:109-114.
8. Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, Lenhof H, Ruprecht K, Meese E. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PloS One 2009, 4(10):e7440. 10.1371/journal.pone.0007440, 2757919, 19823682.
9. Vorwerk S, Ganter K, Cheng Y, Hoheisel J, Stähler PF, Beier M. Microfluidic-based enzymatic on-chip labeling of miRNAs. New Biotechnol 2008, 25(2-3):142-149.
10. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006, 34(Database issue):D140-144. [PMID: 16381832], 1347474, 16381832.
11. Griffiths-Jones S. miRBase: the microRNA sequence database. Methods in Mol Biol (Clifton, N.J.) 2006, 342:129-138.
12. R Development Core Team R: A Language and Environment for Statistical Computing 2010, R Foundation for Statistical Computing, Vienna, Austria, [http://www.R-project.org/. [ISBN 3-900051-07-0]], R Development Core Team.
13. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Statist Soc B 1995, 57:289-300.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif 2001, 25(4):402-408.
15. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866. 10.1038/nrc1997, 17060945.
16. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838. 10.1038/nature03702, 15944708.
17. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clinical Oncol 2011, 8(8):467-477.
18. Hoekstra M, van der Lans CAC, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, van Berkel TJC, Biessen EAL. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 2010, 394(3):792-797. 10.1016/j.bbrc.2010.03.075, 20230787.
19. Keller A, Backes C, Leidinger P, Kefer N, Boisguerin V, Barbacioru C, Vogel B, Matzas M, Huwer H, Katus HA, Cord Stähler BM, Meese E. Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol BioSyst, in press.
20. Liu Y, Wang X, Jiang J, Cao Z, Yang B, Cheng X. Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. Mol Immunol 2011, 48(9-10):1084-1090. 10.1016/j.molimm.2011.02.001, 21367459.
21. Zhang Y, Liao J, Zeng SX, Lu H. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Reports 2011, 12(8):811-817. [PMID: 21637297], 10.1038/embor.2011.98, 3147276, 21637297.
22. Kato M, Wang L, Putta S, Wang M, Yuan H, Sun G, Lanting L, Todorov I, Rossi JJ, Natarajan R. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-beta-induced collagen expression in kidney cells. J Biol Chem 2010, 285(44):34004-34015. 10.1074/jbc.M110.165027, 2962500, 20713358.
23. Silva J, Garcia V, Zaballos A, Provencio M, Lombardia L, Almonacid L, Garcia JM, Dominguez G, Pena C, Diaz R, Herrera M, Varela A, Bonilla F. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. The Eur Respir J: Official J Eur Soc for Clin Respir Physiol 2011, 37(3):617-623.
24. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J of Immunopathology and Pharmacol 2010, 23(4):1229-1234.
25. Wang W, Peng B, Wang D, Ma X, Jiang D, Zhao J, Yu L. Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer J Int Du Cancer 2011, 129(7):1624-1634.
26. Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Cli Cancer Res: An Official J Am Assoc for Cancer Res 2011, 17(6):1463-1473.
27. Saal S, Harvey SJ. MicroRNAs and the kidney: coming of age. Curr Opin in Nephrology and Hypertens 2009, 18(4):317-323.
28. Ho J, Pandey P, Schatton T, Sims-Lucas S, Khalid M, Frank MH, Hartwig S, Kreidberg JA. The pro-apoptotic protein Bim is a microRNA target in kidney progenitors. J Am Soc of Nephrology: JASN 2011, 22(6):1053-1063.
29. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, Vyzula R. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J of Exp & Clin Cancer Res: CR 2010, 29:90. 10.1186/1756-9966-29-90, 23368054.
30. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM. The VHL-dependent regulation of microRNAs in renal cancer. BMC Medicine 2010, 8:64. 10.1186/1741-7015-8-64, 2978113, 20964835.
31. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. The J of Urology 2010, 183(2):743-751.
32. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takanashi M, Kuroda M. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 2011, 102(12):2264-2271. 10.1111/j.1349-7006.2011.02081.x, 21883694.
33. Tao J, Wu D, Li P, Xu B, Lu Q, Zhang W. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol Med R 2012, 5:167-172.
34. Valladares-Ayerbes M, Blanco M, Haz M, Medina V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Reboredo M, Santamarina I, Figueroa A, Antón-Aparicio LM, Calvo L. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer. Int J Oncol 2011, 39(5):1253-1264.
35. Powers MP, Alvarez K, Kim H, Monzon FA. Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping. Diagnostic Mol Pathol: The Am J Surgical Pathol, Part B 2011, 20(2):63-70.
36. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H, Avivi C, Rosenblatt K, Polak-Charcon S, Ramon J, Rosenfeld N, Spector Y. Accurate molecular classification of renal tumors using microRNA expression. The J Mol Diagnostics: JMD 2010, 12(5):687-696.
37. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 2010, 4:51. 10.1186/1752-0509-4-51, 2876063, 20420713.